A Society That Recognizes the Value of Innovation Creates the Next Innovation [Special Contribution]
- Input
- 2026-11-18 06:00:00
- Updated
- 2026-11-18 06:00:05

[Financial News] New possibilities are opening up for diseases that were once difficult to treat. Advances in medicine and science and technology are making it possible to identify the causes of diseases more accurately and develop new treatments that target them directly. One innovation is becoming the starting point for the next.
With Drug Day on November 18, this is a time to reconsider the value of medicines and the conditions needed to sustain innovation. Medicines have changed human lives by expanding the possibilities for treating countless diseases. The value of innovative new drugs lies not only in the development of new treatment technologies. It also lies in opening up new treatment options for patients who have not achieved sufficient results with existing treatments, and helping them regain their health and return to their daily lives.
Where do people see the value of innovative new drugs? In a 2026 survey of 3,055 adults nationwide aged 19 to 69 conducted by Gallup Korea, the largest share of respondents chose “treating disease and restoring health” (31.9%), followed by “improving quality of life” (23.1%) and “reducing socioeconomic burdens” (15.1%). The findings support the view that the value of innovative new drugs extends beyond treatment to patients’ daily lives and society as a whole.
Evidence is also steadily accumulating that the introduction of new drugs can bring socioeconomic benefits in addition to improving patient survival and health. A 2022 study by Frank R. Lichtenberg, a professor at Columbia University's Graduate School of Business, found that the introduction of new drugs helped extend patients’ lives in 26 high-income countries. A study covering 29 European countries, published in June 2026 by the European Federation of Pharmaceutical Industries and Associations (EFPIA), also found that the use of new drugs was associated with reductions in premature deaths and days spent in hospital. This shows that new drugs can do more than save patients’ lives: they can also reduce medical costs and social burdens.
Although various studies have confirmed the clinical and socioeconomic value of new drugs, there is a considerable gap between society’s expectations for the value of innovative new drugs and actual spending levels. According to a domestic study published in 2024, spending on new drugs accounted for an average of 13.5% of South Korea’s total pharmaceutical expenditure from 2017 to 2022, a relatively low share compared with major countries. It did not reach even half of the OECD average of 33.9% or the 38.0% average for the eight countries (A8) South Korea refers to when setting drug prices. In 2022, the gap widened further, with the share at 16.0% in South Korea compared with an A8 average of 48.1%.
Of course, the share of spending on new drugs alone cannot determine patients’ access to treatment. Drug pricing systems, health insurance systems, and the environments in which medicines are used differ from country to country. Even so, this gap prompts us to consider how appropriately South Korea is assessing the value of innovative new drugs.
The government also faces considerable challenges. It must improve patients’ access to new drugs while considering the sustainability of health insurance finances, and it cannot afford to neglect either in a situation where the financial burden is growing due to an aging population and rising demand for healthcare.
Ultimately, the focus is on where and how to use limited resources. This requires a system that comprehensively evaluates not only the clinical effects of new drugs but also improvements in patients’ quality of life and wider social benefits, and provides reasonable compensation in line with that value. Recognizing the value of innovation and ensuring the sustainability of health insurance finances are not conflicting goals; they are tasks that must be pursued together to make more effective use of limited resources.
Reasonable compensation for innovation is a driving force for further innovation. Bringing a single new drug to patients takes years of research, countless failures, and enormous investment. Only when there is confidence that the results will be fairly evaluated can research, development, and investment continue, creating a virtuous cycle that leads to the development of new treatments.
It is encouraging that South Korea’s drug pricing system is now changing in a direction that more actively recognizes the value of innovation. The key now is to consistently reflect this policy direction in specific evaluation and compensation standards, and ensure that the results translate into expanded treatment opportunities for patients.
We hope this Drug Day will serve not only as a time to reflect on the value of medicines, but also as an opportunity to create an environment where new treatments patients need can be continuously developed and supplied. The Korea Research-based Pharmaceutical Industry Association (KRPIA) will also continue working with the government, the medical community, patient groups, and other stakeholders to improve access to new drugs and foster a sustainable innovation ecosystem.
/Oh Dong-wook, Vice Chairman of the Korea Research-based Pharmaceutical Industry Association (KRPIA)